Category Archives: Corporate

Latest From Corporate

Jim Greenwood Op-Ed: Time to Fund Medical Countermeasures against Threats like Ebola

Jim Greenwood

On Friday, The Hill published an op-ed from BIO President and CEO Jim Greenwood calling on Congressional appropriators to fully fund federal biodefense programs, which partner with industry to develop medical countermeasures against Ebola as well as other threats like smallpox, anthrax, and botulism toxin. President Obama’s supplemental Ebola funding request last week asked Congress to appropriate $157 million in funding for BARDA and $238 million for the National Institutes of Health to support Ebola Read More >

Jim's Corner  |  Leave a comment  |  Email This Post
Tags: , , ,

Gates to contribute $50M for Ebola response

admin-ajax

Bill Gates was on MSNBC’s Morning Joe to discuss the Gates Foundation’s contribution of $50 million to support emergency response to Ebola. Mr. Gates responded to criticism that the U.S. was initially slow to properly address the African crisis. He noted that it would be virtually impossible to respond much quicker to the unprecedented scale of the outbreak. He did call upon other countries to step up and dedicate resources as well. The most recent Read More >

Corporate, Events  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

San Francisco Chronicle: High Drug Co-Pays Deny Needed Treatments

Jim Greenwood

Today, the San Francisco Chronicle published an op-ed that I wrote on the importance of ensuring access to treatments for debilitating diseases that are saving millions of patients from pain and possible death. Patients rightly expect their health insurance plan to cover the best medicines based on their unique needs, at an out-of-pocket cost that makes these therapies accessible. Insurance companies and their allies, seeking to deflect blame for increased premiums at a time of Read More >

Jim's Corner  |  Leave a comment  |  Email This Post
Tags: , , , , ,

Jim Greenwood in WSJ: Curing Hepatitis C Is Cheaper Than Open-Ended Care

Jim Greenwood

On Friday, a letter from BIO President and CEO Jim Greenwood was published in the Wall Street Journal, arguing that curing hepatitis C is cheaper than the alternative of open ended care. The full text of the letter is below: President and CEO of America’s Health Insurance Plans (HIP) Karen Ignagni’s “Paying for the Thousand-Dollar Pill” (op-ed, Aug. 4) plays down the fact that Sovaldi has been shown to achieve a high cure rate for Read More >

Jim's Corner  |  Leave a comment  |  Email This Post
Tags: , ,

Delivering on Biotech’s Promise to Treat Anthrax, Smallpox, Ebola

Jim Greenwood

Thanks to federal biodefense programs that partner with industry to develop and stockpile medical countermeasures, each year America is better equipped to respond to potential biological, chemical, nuclear and radiological threats, BIO president and CEO Jim Greenwood says in a Roll Call op-ed published today. With recent anthrax and smallpox incidents at CDC and NIH labs,  which fortunately did not lead to any human exposure,  it’s worth taking a look at how we might respond Read More >

Jim's Corner  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,